Literature DB >> 6736649

Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes.

E Jouvin-Marche, E Ninio, G Beaurain, M Tence, P Niaudet, J Benveniste.   

Abstract

Human polymorphonuclear neutrophils, monocytes, and lymphocytes were studied for their ability to synthesize Paf-acether when stimulated with the ionophore A 23187 (Io) or with specific secretagogues. When stimulated with Io, neutrophils produced 100 +/- 8.5 pmol Paf-acether 1 X 10(6) cells (mean +/- 1 SD, n = 5); monocytes were less efficient (44 +/- 3.3 pmol Paf-acether/1 X 10(6) cells), whereas lymphocytes were practically unable to form this mediator (1.0 +/- 0.4 pmol Paf-acether/1 X 10(6) cells). Neutrophils and monocytes released in the extracellular medium 49 and 37% of Paf-acether that they formed, respectively. We attempted to correlate the amount of Paf-acether produced by the various cell types with that of its precursors, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine and 1-O-alkyl-sn-glycero-3-phosphocholine (2-lyso Paf-acether). In the three cell types, the amount of 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine was sufficient to ensure the formation of 2-lyso Paf-acether and consequently that of Paf-acether. The quantity of 2-lyso Paf-acether formed appeared to be the limiting factor only in the case of the neutrophils. These cells increased their synthesis of Paf-acether in the presence of exogenous 2-lyso Paf-acether. To investigate the failure of lymphocytes to produce the mediator, the acetylating step of Paf-acether formation was studied, and we found a very weak activity (0.5 +/- 0.1 nmol Paf-acether/10 min/mg protein) in this cell type as opposed to monocytes (4.0 +/- 2.3 nmol Paf-acether/10 min/mg protein) and neutrophils (17.8 +/- 5.3 nmol Paf-acether/10 min/mg protein). These activities were doubled in Io-stimulated cells. Thus, the modulation of acetyl-transferase activity appears to be a key step in the regulation of Paf-acether biosynthesis. Also, the availability of 2-lyso Paf-acether could regulate Paf-acether synthesis in human neutrophils.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736649

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Regulation of the biosynthesis of platelet-activating factor in alveolar macrophages.

Authors:  T Sugiura; A Ojima-Uchiyama; Y Masuzawa; M Fujita; Y Nakagawa; K Waku
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Determination of platelet-activating factor by a chemiluminescence method and its application to stimulated guinea pig neutrophils.

Authors:  Y Hasegawa; E Kunow; J Shindou; H Yuki
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 3.  Pharmacological studies of pulmonary anaphylaxis in vitro: a review.

Authors:  P O Ogunbiyi; P Eyre
Journal:  Agents Actions       Date:  1985-12

4.  Effect of Staphylococcus aureus delta-toxin on human granulocyte functions and platelet-activating-factor metabolism.

Authors:  S Kasimir; W Schönfeld; J E Alouf; W König
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig.

Authors:  L Beijer; J Botting; P Crook; A O Oyekan; C P Page; R Rylander
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

6.  Intracellular platelet-activating factor regulates eicosanoid generation in guinea-pig resident peritoneal macrophages.

Authors:  A G Stewart; W A Phillips
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  Biosynthesis of paf-acether. Paf-acether but not leukotriene C4 production is impaired in cultured macrophages.

Authors:  A Dulioust; E Vivier; N Meslier; R Roubin; I Haye-Legrand; J Benveniste
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

8.  Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.

Authors:  P Hilliquin; J Natour; J Aissa; P Guinot; S Laoussadi; J Benveniste; C J Menkes; B Arnoux
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

9.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine.

Authors:  C A Demopoulos; N K Andrikopoulos; S Antonopoulou
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

10.  Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin.

Authors:  I Sobhani; Y Denizot; S Hochlaf; D Rigaud; J Vatier; J Benveniste; M J Lewin; M Mignon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.